Maximus, Inc. (NYSE:MMS) Director Paul R. Lederer sold 2,200 shares of the stock in a transaction dated Monday, August 14th. The stock was sold at an average price of $60.87, for a total value of $133,914.00. The sale was disclosed in a document filed with the SEC, which is available at this link.

Shares of Maximus, Inc. (NYSE:MMS) traded up 0.67% during trading on Monday, reaching $61.24. 63,392 shares of the company traded hands. The firm’s 50 day moving average is $61.19 and its 200-day moving average is $60.86. Maximus, Inc. has a 12-month low of $43.69 and a 12-month high of $64.97. The stock has a market capitalization of $3.97 billion, a P/E ratio of 19.63 and a beta of 1.39.

Maximus (NYSE:MMS) last announced its quarterly earnings data on Thursday, August 3rd. The health services provider reported $0.79 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.76 by $0.03. The business had revenue of $600.40 million for the quarter, compared to analysts’ expectations of $614.12 million. Maximus had a net margin of 8.43% and a return on equity of 25.08%. The business’s revenue was down 2.7% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.79 earnings per share. On average, equities research analysts anticipate that Maximus, Inc. will post $3.12 earnings per share for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, August 31st. Shareholders of record on Tuesday, August 15th will be issued a $0.045 dividend. This represents a $0.18 dividend on an annualized basis and a yield of 0.30%. The ex-dividend date is Friday, August 11th. Maximus’s dividend payout ratio (DPR) is presently 5.73%.

COPYRIGHT VIOLATION WARNING: This piece of content was originally posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this piece of content on another website, it was stolen and republished in violation of international copyright and trademark laws. The correct version of this piece of content can be read at https://www.thecerbatgem.com/2017/08/14/maximus-inc-mms-director-sells-133914-00-in-stock.html.

Several large investors have recently bought and sold shares of MMS. BlackRock Inc. boosted its stake in Maximus by 22,491.0% in the first quarter. BlackRock Inc. now owns 6,503,511 shares of the health services provider’s stock worth $404,518,000 after buying an additional 6,474,723 shares during the last quarter. Vanguard Group Inc. boosted its stake in Maximus by 2.4% in the second quarter. Vanguard Group Inc. now owns 5,669,026 shares of the health services provider’s stock worth $355,052,000 after buying an additional 130,839 shares during the last quarter. FMR LLC boosted its stake in Maximus by 10.4% in the second quarter. FMR LLC now owns 4,658,584 shares of the health services provider’s stock worth $291,767,000 after buying an additional 438,025 shares during the last quarter. William Blair Investment Management LLC boosted its stake in Maximus by 14.7% in the first quarter. William Blair Investment Management LLC now owns 4,416,279 shares of the health services provider’s stock worth $274,693,000 after buying an additional 566,292 shares during the last quarter. Finally, Victory Capital Management Inc. boosted its stake in Maximus by 8.6% in the second quarter. Victory Capital Management Inc. now owns 3,100,903 shares of the health services provider’s stock worth $194,210,000 after buying an additional 244,823 shares during the last quarter. Hedge funds and other institutional investors own 97.20% of the company’s stock.

Several analysts have recently commented on the company. Canaccord Genuity downgraded Maximus from a “buy” rating to a “hold” rating and set a $62.00 target price for the company. in a research note on Tuesday, July 4th. Jefferies Group LLC downgraded Maximus from a “buy” rating to a “hold” rating and raised their target price for the company from $63.00 to $64.00 in a research note on Friday, May 5th. Maxim Group downgraded Maximus from a “buy” rating to a “hold” rating and set a $66.00 target price for the company. in a research note on Thursday, May 4th. They noted that the move was a valuation call. ValuEngine downgraded Maximus from a “buy” rating to a “hold” rating in a research note on Tuesday, May 16th. Finally, KeyCorp restated a “sector weight” rating on shares of Maximus in a research note on Thursday, May 25th. One equities research analyst has rated the stock with a sell rating and eight have assigned a hold rating to the company. The stock has an average rating of “Hold” and an average price target of $62.17.

About Maximus

MAXIMUS, Inc provides business process services (BPS) to government health and human services agencies. The Company operates through three segments: U.S. Federal Services, Health Services and Human Services. The U.S. Federal Services segment provides BPS and program management for large government programs, independent health review and appeals services for both the United States Federal Government, and state-based programs and technology solutions for civilian federal programs.

Insider Buying and Selling by Quarter for Maximus (NYSE:MMS)

Receive News & Stock Ratings for Maximus Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Maximus Inc. and related stocks with our FREE daily email newsletter.